• 1
    Blot WJ,McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 5( Suppl 15): 28.
  • 2
    Osugi H,Takemura M,Higashino M,Takada N,Lee S,Ueno M,Tanaka Y,Fukuhara K,Hashimoto Y,Fujiwara Y,Kinoshita H. Causes of death and pattern of recurrence after esophagectomy and extended lymphadectomy for squamous cell carcinoma of the thoracic esophague. Oncol Reports 2003; 10: 817.
  • 3
    Wu DL,Sui FY,Jiang XM,Jiang XH. Methylation in esophageal carcinogenesis. World J Gastroenterol 2006; 12: 693340.
  • 4
    Lee EJ,Lee BB,Kim JW,Shim YM,Hoseok I,Han J,Cho EY,Park J,Kim DH. Aberrant methylation of fragile histidine triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 2006; 42: 97280.
  • 5
    Brock MV,Gou M,Akiyama Y,Muller A,Wu TT,Montgomery E,Deasel M,Germonpre P,Rubinson L,Heitmiller RF,Yang SC,Forastiere AA, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003; 9: 291219.
  • 6
    Guo M,Ren J,House MG,Qi Y,Brock MV,Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 2006; 12: 451522.
  • 7
    Ishii T,Murakami J,Notohara K,Cullings HM,Sasamoto H,Kambara T,Shirakawa Y,Naomoto Y,Ouchida M,Shimizu K,Tanaka N,Jass JR, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007; 56: 1319.
  • 8
    Xing EP,Nie Y,Wang LD,Yang GY,Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian. China Carcinogenesis 1999; 20: 7784.
  • 9
    Tokugawa T,Sugihara H,Tani T,Hattori T. Modes of silencing of p16 in development of esophageal squamous cell carcinoma. Cancer Res 2002; 62: 493444.
  • 10
    Hibi K,Taguchi M,Nakayama H,Hattori T. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001; 7: 31358.
  • 11
    Nie Y,Liao J,Zhao X,Song Y,Yang GY,Wang LD,Yang CS. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 2002; 23: 171320.
  • 12
    Xing EP,Nie Y,Song Y,Yang GY,Cai YC,Wang LD,Yang CS. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a in human esophageal squamous cell carcinoma. Clin Cancer Res 1999; 5: 270413.
  • 13
    Takeno S,Noguchi T,Fumoto S,Kimura Y,Shibata T,Kawahara K. E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Am J Clin Pathol 2004; 122: 7884.
  • 14
    Wang Y,Fang MZ,Liao J,Yang GY,Nie Y,Song Y,So C,Xu X,Wang LD,Yang CS. Hypermethylation-associated inactivation of retinoic acid receptor beta in human esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 525763.
  • 15
    Kuroki T,Trapasso F,Yendamuri S,Matsuyama A,Alder H,Mori M,Croce CM. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003; 63: 37248.
  • 16
    Taniguchi H,Yamamoto H,Hirata T,Miyamoto N,Oki M,Nosho K,Adachi Y,Endo T,Imai K,Shinomura Y. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005; 24: 794652.
  • 17
    Fleming ID. American Joint Committee on Cancer Classification (AJCC). AJCC cancer staging manual. Philadelphia: Lippincott, 1997.
  • 18
    Herman JG,Graff JR,Myöhänen S,Nelkin BD,Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 98216.
  • 19
    Orsulic S,Huber O,Aberle H,Arnold S,Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 1999; 112: 123745.
  • 20
    Stockinger A,Eger A,Wolf J,Beug H,Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J Cell Biol 2001; 154: 118596.
  • 21
    Gottardi CJ,Wong E,Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 2001; 153: 104960.
  • 22
    Piedra J,Miravet S,Castaño J,Pálmer HG,Heisterkamp N,de Herreros AG,Duñach M. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol 2003; 23: 228797.
  • 23
    Roura S,Miravet S,Piedra J,de Herreros AG,Duñach M. Regulation of E-cadherin/Catenin Association by Tyrosine Phosphorylation. J Biol Chem 1999; 274: 3673440.
  • 24
    Ai L,Tao Q,Zhong S,Fields CR,Kim WJ,Lee MW,Cui Y,Brown KD,Robertson KD. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006; 27: 13418.
  • 25
    Urakami S,Shiina H,Enokida H,Kawakami T,Tokizane T,Ogishima T,Tanaka Y,Li LC,Ribeiro-Filho LA,Terashima M,Kikuno N,Adachi H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 2006; 12: 38391.
  • 26
    Tang M,Torres-Lanzas J,Lopez-Rios F,Esteller M,Sanchez-Cespedes M. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer 2006; 119: 26036.
  • 27
    He B,Reguart N,You L,Mazieres J,Xu Z,Lee AY,Mikami I,McCormick F,Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005; 24: 30548.
  • 28
    Batra S,Shi Y,Kuchenbecker KM,He B,Reguart N,Mikami I,You L,Xu Z,Lin YC,Clément G,Jablons DM. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 2006; 342: 122832.
  • 29
    Mazieres J,He B,You L,Xu Z,Lee AY,Mikami I,Reguart N,Rosell R,McCormick F,Jablons DM. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004; 64: 471720.
  • 30
    Polakis P. Casein kinase 1: a Wnt'er of disconnect. Curr Biol 2002; 12: R499R501.
  • 31
    Cano A,Perez-Moreno MA,Rodrigo I,Locascio A,Blanco MJ,del Barrio MG,Portillo F,Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 7683.
  • 32
    Ciruna B,Rossant J. FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. Dev Cell 2001; 1: 3749.
  • 33
    Hsieh JC,Kodjabachian L,Rebbert ML,Rattner A,Smallwood PM,Samos CH,Nusse R,Dawid IB,Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999; 398: 4316.
  • 34
    Nishita M,Hashimoto MK,Ogata S,Laurent MN,Ueno N,Shibuya H,Cho KWY. Interaction between Wnt and TGF-? Signalling pathways during formation of Spemann's organizer. Nature 2000; 403: 7815.
  • 35
    Riese J,Yu X,Munnerlyn A,Eresh S,Hsu SC,Grosschedl R,Bienz M. LEF-1, a Nuclear Factor Coordinating Signaling Inputs from wingless and decapentaplegic. Cell 1997; 88: 77787.
  • 36
    Braakhuis BJM,Brakenhoff RH,Leemans CR. Second field tumors: a new opportuinity for cancer prevention? Oncologist 2005; 10: 493500.
  • 37
    Slaughter DP,Southwick HW,Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Cancer (Phila.) 1953; 6: 9638.